| INTRODUCTION
Intercellular tight junctions provide structural integrity to epithelial and endothelial tissues, serving as highly polarized barriers vital for maintaining homeostasis. Occludin is a membrane linker protein essential for the stability and function of intercellular tight junctions. 1 In 2010, mutations in OCLN were identified as a cause of band-like calcification with simplified gyration and polymicrogyria (BLC-PMG), an autosomal recessive syndrome with prenatal onset. 2 Patients with BLC-PMG present with clinical and neuro-radiological features which can mimic the sequelae of congenital infection (a so-called pseudo-
TORCH phenotype).
Full length OCLN consists of 9 exons encoding a protein of 522 amino acids, situated on chromosome 5 (69 492 292-69 558 104; GRCh38). In addition to the full length protein-coding gene, an OCLN pseudogene (UCSC ID: LOC647859) also exists on chromosome 5,~1.5 Mb upstream within a 500 kb inverted duplication. 3 The genetic architecture of this region is highly complex in its organization and consists of an assortment of smaller duplicated segments. A schematic depicting a simplified version of the region is shown in Figure 1A . The pseudogene is made up of exons 5 to 9, which show 99.75% homology with the full-length gene ( Figure 1B ). Copy number state of the duplicated portion of OCLN is also highly variable, so that the total number of copies (gene plus pseudogene) of exons 5 to 9 ranges from 2 to >5. Individuals with a copy number of 2 possess only the full-length protein-coding version of OCLN, with this state being more frequently seen in East and South-East Asian populations. 4 
| PCR and Sanger sequencing
Genomic DNA was extracted from the lymphocytes of affected individuals and parents using standard techniques. Polymerase chain reaction (PCR) was performed using Abgene AB575 master mix and sequencing carried out using BigDye terminator cycle sequencing system v3.1. All primers were designed using Primer3 software (Table S1 , Supporting Information). 6 Novel variants were analyzed using Alamut visual 2.7 (Interactive Bio-software).
| Cell culture
EBV transformed LCLs were established using standard techniques.
Cells were maintained in Roswell Park Memorial Institute medium (RPMI) (Gibco, Fisher Scientific, Loughborough, UK) supplemented with 10% Fetal Bovine Serum (FBS) (Sigma, Sigma-Aldrich, Dorset, UK) and 1% penicillin-streptomycin (Gibco).
| RNA extraction and cDNA synthesis
One confluent T75 flask of LCL cells was used per RNA extraction. RNA was extracted from cell pellets using the TRI Reagent Solution (Ambion, Fisher Scientific, Loughborough, UK) in accordance with the manufacturer's instructions. After RNA extraction, reverse transcriptase PCR was performed with the ABI High capacity RNA to cDNA kit to obtain cDNA samples in accordance with the manufacturer's instructions.
| Copy number analysis
Copy number analysis was performed using a custom FAM-labeled Taq 
| RESULTS
Using copy number analysis combined with genomic and cDNA sequencing we developed a screening strategy for accurate mutation detection in patients with suspected BLC-PMG ( Figure 2 ; Table S2) .
Below, we demonstrate how this workflow has been used to identify novel OCLN mutations in 4 families.
| Copy number analysis
The first stage in the BLC-PMG screening strategy is to determine the copy number of the OCLN gene. Given that the copy number state of the duplicated portion of OCLN is highly variable, the purpose of this Figure 3B ), indicating that they do not carry the pseudogene.
| Molecular screening of patients with BLC-PMG
Once the presence or absence of the pseudogene was determined in our families the most appropriate sequencing strategy was selected. Where the pseudogene is absent, standard genomic sequencing was applied to screen for mutations. Using this strategy we detected a homozygous deletion in exon 7 of OCLN (c.1284_1287del, p.Gln428Hisfs*56) in patient F523. Parental DNA was unavailable for segregation analysis.
In contrast, patients found to carry copies of the pseudogene were screened using a combination of genomic and cDNA sequencing in order to accurately identify causative mutations. Given the lack of Occludin expression in whole blood, an EBV-transformed lymphoblastoid cell line was first established to provide sufficient amounts of cDNA for screening. Exons 2 to 4 were examined using standard genomic sequencing (the OCLN start codon lies in exon 2, so that exon 1 is excluded from the analysis). LCLs contain alterna- Schematic illustrating the occludin (OCLN) screening strategy used in this report. The initial step is to determine the presence or absence of the OCLN pseudogene using a Taqman copy number assay designed to target exon 9. Once the copy number state has been determined the most appropriate sequencing analysis can be used to enable fully comprehensive screening and accurate variant annotation. Given alternative splicing transcripts exclusively involving exons 3 and 4, genomic sequencing of exons 2 to 4 is appropriate even in the presence of pseudogene copies
It was therefore reasoned that the pseudogene was masking the mutant allele in these individuals. The terminal half of LCL-derived OCLN cDNA was then amplified, and sequencing confirmed that the OCLN transcript is mis-spliced, resulting in the loss of 37 nucleotides from the end of exon 6 (p.Glu407Asnfs*66) ( Figure 4B ). The proband is homozygous for the mis-spliced transcript, whilst both parents were shown to be heterozygous carriers. This example shows the importance of sequencing the 3′ end of the OCLN gene in cDNA for individuals that have the pseudogene, the presence of which can mask a homozygous variant and make it appear as heterozygous in genomic sequencing traces.
The combined screening technique also identified a novel OCLN mutation in exon 7 of patient F468. Genomic and cDNA sequencing carried out in the affected individual and parents defined a homozygous frameshift (c.1320_1336del, p.Gln441Thrfs*5) in the proband, and confirmed both parents to be heterozygous carriers.
Finally, genomic sequencing of patient F557 identified a homozygous complex indel (c.711_714delinsATCCCCAGTA, p.C237X) in exon 3 of OCLN. Parental DNA was not available.
A summary of the novel mutations described above can be found in Table 1 and Figure 1C . All of the variants identified are predicted to be pathogenic, and all are absent from the Exome Aggregation Consortium (ExAC) browser which contains more than 112 000 annotated alleles across OCLN (http://exac.broadinstitute.org-Accessed
October 11, 2016).
| DISCUSSION
The first molecular defects in OCLN were described by O'Driscoll et al as the genetic cause of BLC-PMG. failure (the precise nature of which was undefined), prompting the authors to suggest that kidney disease may be a consistent feature of BLC-PMG. 9 Considering that F523 in this report also developed features of nephrogenic diabetes insipidus at age 20 months, we would concur with this suggestion and recommend that patients mutated in OCLN should undergo regular renal monitoring. A summary of all reported pathogenic OCLN variants is given in Table 1 and Figure 1C . To conclude, we report 4 new cases of BLC-PMG associated with mutations in OCLN. The novel variants described here were all detected using copy number analysis and a combination of genomic and cDNA sequencing. We suggest that this strategy can be used to overcome the technical challenges associated with genetic screening of BLC-PMG, thus allowing accurate diagnosis and genetic counseling.
